Company / Cost of Revenue
NeoGenomics Laboratories, Inc. Cost of Revenue History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cost of Revenue
$413.0M
FY2025
5-year range
$297.3M / $413.0M
FY2021-FY2025
Trend
+11.5%
vs FY2024
Sector context
#70 of 113
Health Care
What the data says
At $413M, NeoGenomics Laboratories, Inc.'s cost of revenue ranks #44 of 113 in the Health Care sector. Cost of Revenue has increased for 9 consecutive years, from $134M in FY2016 to $413M in FY2025.
Based on SEC 10-K filings.
$413M in FY2025 with a 5-year CAGR of +9.8%.
Increased from $347M to $413M over the past 2 years.
Health Care sector context is included.
Cost of Revenue over time
Growth rates
- 3-Year CAGR
- +8.7%
- 5-Year CAGR
- +9.8%
- 10-Year CAGR
- -
Sector benchmark
#44 of 113 in Health CareTop 38% of 113This company $413.0M Sector average $11.3B
▼
-96.3% below sector average
Key checks
Key Insights
- NeoGenomics Laboratories, Inc.'s cost of revenue has grown for 9 consecutive years.
- 5-year CAGR of +9.8%, indicating consistent growth.
- In FY2025, cost of revenue increased 11.5% year-over-year.
- Ranks #70 out of 113 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 0.56 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cost of RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $413.0M | +11.5% |
| FY2024 | $370.5M | +6.8% |
| FY2023 | $347.0M | +7.8% |
| FY2022 | $321.8M | +8.3% |
| FY2021 | $297.3M | +15.0% |
| FY2020 | $258.6M | +22.0% |
| FY2019 | $212.0M | +41.8% |
| FY2018 | $149.5M | +8.1% |
| FY2017 | $138.3M | +3.4% |
| FY2016 | $133.7M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026